Nurix Therapeutics (NRIX)’ treatment of Waldenstrom macroglobulinemia was granted FDA orphan designation, according to a post on the agency’s ...
Zacks Investment Research on MSN19h
ProQR (PRQR) Reports Q4 Loss, Lags Revenue EstimatesProQR (PRQR) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.08 per share a year ago. These figures are adjusted ...
Zymeworks (ZYME) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...
DelveInsight’s, “Mesothelioma Pipeline Insight 2025” report provides comprehensive insights about 45+ companies and 50+ ...
March 11, 2025 Barclays 27th Annual Global Healthcare Conference, Miami Beach, FL Fireside chat: March 12, 2025, from ...
At the time, its anchor tenant, San Francisco-based Nurix Therapeutics Inc. (Nasdaq: NRIX), said it expected to hire between 75 and 100 science and executive jobs in The Woodlands. Another life ...
Nurix Therapeutics, Inc. is a San Francisco based early clinical-stage biotechnology concern focused on leveraging its expertise in cellular protein modulation to develop therapies against ...
Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated cancers, especially mCRC. See why I rate CRDF stock as a strong buy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback